Sol-Gel Reports First Quarter 2025 Results

Sol-Gel Technologies (SLGL) reported Q1 2025 revenue of $1 million, up from $0.5 million in Q1 2024, but a net loss of $8.8 million, increasing from $6.3 million in the same period last year, primarily due to increased R&D expenses related to SGT-610 commercialization and EPSOLAY/TWYNEO expansion outside the U.S. Despite the increased loss, the company's cash reserves of $16.9 million are expected to fund operations into Q1 2027.

Analysis

Sol-Gel Technologies (NASDAQ: SLGL) reported Q1 2025 revenues of $1.0 million, doubling from $0.5 million in Q1 2024, driven by license revenues. Despite this growth, the company's net loss widened to $8.8 million ($3.2 per share) from $6.3 million ($2.3 per share) year-over-year. This was primarily due to research and development (R&D) expenses increasing by $3.5 million to $8.8 million, mainly reflecting a $3.6 million rise for SGT-610 supplier-led manufacturing development and $0.5 million for international commercialization of EPSOLAY and TWYNEO, partially offset by a $0.5 million decrease in SGT-610 clinical trial costs. General and administrative expenses fell to $1.3 million from $1.8 million due to cost-saving measures. As of March 31, 2025, Sol-Gel's cash and cash equivalents stood at $16.9 million; the company liquidated its $4.425 million in marketable securities during the quarter, resulting in a net $7.024 million decrease in combined cash, cash equivalents, and marketable securities from December 31, 2024. Management projects these cash resources will fund operations into Q1 2027, while advancing its dermatology pipeline, including SGT-610, and supporting its commercial products.

Key Decisions for Investors

• Investors should weigh the doubling of revenue against the significantly wider net loss and the $7.024 million quarterly reduction in cash and marketable securities, which was driven by strategic R&D investments for SGT-610 and international product expansion.
• While management's projection of a cash runway into Q1 2027 offers some operational stability, careful monitoring of the actual cash burn rate against this forecast is essential, particularly considering the current quarter's expenditure and the inherent uncertainties in R&D and commercialization timelines.
• Key developments to monitor include clinical trial progress for SGT-610, revenue ramp-up from EPSOLAY and TWYNEO, especially in ex-U.S. markets, and any new collaboration agreements, as these will be critical determinants of the company's financial outlook and valuation.
• Given the moderately negative sentiment score of -0.45 and the extensive risk factors disclosed, including competition and collaborator dependency, a cautious investment approach is warranted, focusing on the company's ability to execute its strategic commercial and development plans effectively.